Comment
doi: 10.1016/S2213-8587(17)30012-8.
Epub 2017 Jan 17.
Semaglutide: a promising new glucagon-like peptide-1 receptor agonist
Affiliations
- PMID: 28110912
- DOI: 10.1016/S2213-8587(17)30012-8
Item in Clipboard
Comment
Semaglutide: a promising new glucagon-like peptide-1 receptor agonist
Lancet Diabetes Endocrinol.
2017 Apr.
No abstract available
Comment on
-
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.
Similar articles
-
Once-weekly glucagon-like peptide 1 receptor agonists.J Pak Med Assoc. 2015 Jul;65(7):796-8. J Pak Med Assoc. 2015. PMID: 26160096 Review.
-
Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations.Front Endocrinol (Lausanne). 2021 Sep 23;12:760153. doi: 10.3389/fendo.2021.760153. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34630338 Free PMC article. No abstract available.
-
Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.Med Lett Drugs Ther. 2018 Jan 29;60(1539):19-21. Med Lett Drugs Ther. 2018. PMID: 29364197 No abstract available.
-
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.J Med Chem. 2015 Sep 24;58(18):7370-80. doi: 10.1021/acs.jmedchem.5b00726. Epub 2015 Sep 11. J Med Chem. 2015. PMID: 26308095
-
Semaglutide for obesity: four STEPs forward, but more to come.Lancet Diabetes Endocrinol. 2021 May;9(5):252-254. doi: 10.1016/S2213-8587(21)00081-4. Lancet Diabetes Endocrinol. 2021. PMID: 33864806 Review. No abstract available.
Cited by
-
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.PLoS One. 2021 Feb 19;16(2):e0244689. doi: 10.1371/journal.pone.0244689. eCollection 2021. PLoS One. 2021. PMID: 33606705 Free PMC article.
-
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs.Med Rev (2021). 2024 Jun 4;4(4):312-325. doi: 10.1515/mr-2024-0018. eCollection 2024 Aug. Med Rev (2021). 2024. PMID: 39135602 Free PMC article. Review.
-
The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.Acta Pharm Sin B. 2022 Nov;12(11):4040-4055. doi: 10.1016/j.apsb.2022.06.003. Epub 2022 Jun 11. Acta Pharm Sin B. 2022. PMID: 36386481 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
